Exhibit 99.1

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of August 18, 2023, is by and among SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd. (the foregoing are collectively referred to herein as the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.01 per share of Novavax, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

SK bioscience Co., Ltd.
By:	/s/ Jae-Yong Ahn
Name:	Jae-Yong Ahn
Title:	Chief Executive Officer
SK chemicals Co., Ltd.
By:	/s/ Jae-Hyun Ahn
Name:	Jae-Hyun Ahn
Title:	Chief Executive Officer
SK discovery Co., Ltd.
By:	/s/ Kwang-Hyun Jeon
Name:	Kwang-Hyun Jeon
Title:	Chief Executive Officer

Page 9 of 9 Pages